27)
Fukuda-Tsuru, S., et al.：Eur J Pharmacol. 2012；696（1-3）：194-202

28)
Eto, T., et al.：Diabetes Obes Metab. 2012；14（11）：1040-1046

29)
Mather, A., Pollock, C.：Kidney Int. 2011；79（suppl.120）：S1-S6

30)
Kuriyama, C., et al.：J Pharmacol Exp Ther. 2014；351（2）：423-431

31)
田辺三菱製薬（株）：カナグリフロジンの2型糖尿病患者を対象とした臨床薬理試験（社内資料）

32)
田辺三菱製薬（株）：カナグリフロジンのin vitro及びin vivo薬理作用（社内資料）

33)
Inagaki, N., et al.：Expert Opin Pharmacother. 2014；15（11）：1501-1515

文献請求先

主要文献に記載の社内資料につきましても下記にご請求下さい．
第一三共株式会社　製品情報センター

〒103-8426 東京都中央区日本橋本町3-5-1

TEL：0120-189-132

製造販売業者等の氏名又は名称及び住所

製造販売元
田辺三菱製薬株式会社

大阪市中央区道修町3-2-10

販売元
第一三共株式会社

東京都中央区日本橋本町3-5-1
Release of Canary Combination Tablets Japan's first combination of DPP-4 inhibitor and SGLT2 inhibitor
The first combination of DPP-4 inhibitor and SGLT2 inhibitor in Japan
"Canary combination tablet" is a combination preparation containing two components, DPP-4 inhibitor and SGLT 2 inhibitor, first released in Japan. "Tenellia tablets" and "Canagle tablets" are both Japan Origin medicine type 2 diabetes treatment agent created by Mitsubishi Tanabe Pharma. "Canary formulated tablets" containing both drugs can be divided into two groups according to two different mechanisms of action, namely insulin secretion promoting action according to blood glucose level by DPP-4 inhibitor and urinary glucose excretion promoting action by SGLT2 inhibitor, 1 day 1 It is said that good glucose control can be expected with 1 tablet.
In domestic clinical trials for patients who were ineffective in single treatment of "Tenellia tablets" or "Canagle tablets", excellent results were confirmed in the efficacy and safety of "canary mixed tablets".
"Canary combination tablets" can be used by patients with type 2 diabetes whose blood glucose control is stable by the combination treatment of "Tenellia tablets" and "Canagle tablets", which can reduce the number of compressed tablets and lead to an improvement in adherence . For patients with type 2 diabetes who are receiving monotherapy with "Tenellia tablets" or "Canagle tablets", but who have insufficient effectiveness, by improving glycemic control by using this drug Can be expected.
DAIICHI SANKYO and Kanaguru tablets are sold by Tanabe Mitsubishi Pharmaceutical respectively, while DAIICHI SANKYO sells "Canary Combination Tablets" to provide information to medical institutions As for activities, as in "Tenellia tablets" and "Canaglu tablets", both companies will conduct jointly.
Details of canary-containing combination tablets
Sales name Canary combination tablets
Generic name Tenrylyptine hydrobromide hydrate /canagliflozin hydrate combination tablets
Indications and effects Type 2 diabetes
Provided, however, that the treatment with concomitant use of tenergliptin hydrobromide hydrate and canagliflozin hydrate is deemed appropriate.
Dosage / administration Usually 1 tablet once a day (20 mg/100 mg as tenrigliptin/ canaglifujin) is orally administered before breakfast or after breakfast for adults.
Packing canary combination tablet: 100 tablets (10 tablets × 10)
Medicati